Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial
Journal: Arthritis Research & Therapy
Year: 2012

ClinicalTrials.gov: NCT00427934.